retatrutide maximum dose clinical trials Dosing Schedule: From to Real Weight Loss Outcomes People always say my dose

The key difference is retatrutide's dysesthesia (20.9%) versus less than 1% with Wegovy or Mounjaro

Retatrutide remains unlicensed by the MHRA and EMA as of mid-2025

Retatrutide is an investigational triple incretin receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously

RETA treatment dramatically delayed LLC tumor onset, with unpalpable tumors in the RETA treated group until day 16, compared to onset observed in Veh treated mice where tumors were palpated starting on day 10 (Fig

UK Summaries of Product Characteristics (SmPCs) advise caution in people with a history of pancreatitis, severe gastrointestinal disease, or thyroid disease

Compounded GLP-1 options allow for microdosing and personalized escalation, which can enhance safety in higher-risk populations when supervised by a qualified healthcare provider